BMS-582949

Research use only, not for human use.

BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13 nM, inhibiting both p38 kinase activity and activation of p38.

BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13 nM, inhibiting both p38 kinase activity and activation of p38.

——

Animal Model:murine models of acute inflammation from BALB/c female miceDosage:5 mg/kgAdministration:Oral gavage (p.o.), detection content at 90 min after LPS injectionResult:Reduced the TNFα production by 89% at 2 h, by 78% at 6 h before the LPS challenge.Animal Model:Rat adjuvant arthritis (rat AA) models from Male Lewis rats Dosage:1, 10, 100 mg/kg, once daily (q.d)Administration:Oral gavage (p.o.)Result:Reduced paw swelling with dose-dependent, with efficacy observed at doses of 10 and 100 mg/kg.Animal Model:Rat adjuvant arthritis (rat AA) models from Male Lewis rats Dosage:0-5 mg/kg, b.i.d Administration:Oral gavage (p.o.)Result:Improved efficacy markedly of reduction in paw swelling at doses of 1 and 5 mg/kg.Reduced paw swelling significantly at doses as low as 0.3 mg/kg.

——

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

p38 MAPK

Inflammation/Immunology

——

623152-17-0

406.48

C22H26N6O2

>98% (HPLC)

——

CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C

——

(-20℃)

With Ice Pack

≥ 2 years